Levine Leichtman Capital Partners, LLC’s Post

𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐁𝐚𝐫𝐫𝐢𝐞𝐫𝐬: 𝐓𝐨𝐝𝐚𝐲 1 𝐩𝐦 𝐄𝐒𝐓 / 7 𝐩𝐦 𝐌𝐄𝐙 Unlock the Power of FSP Models for Mid-sized Pharma! 🚀 Join our webinar to discover the strategic secrets that transform clinical trial performance. From tailored partnerships to unlocking value, let's revolutionize your trials. Demystify FSP and reshape your CRO engagement game. Don't miss the ride! https://lnkd.in/eEPv4Sjw #FSP360 #syneoshealth #gamechanger

Large pharmaceutical companies often favor adopting functional service provider (FSP) models over full-service outsourcing across their clinical and R&D operations. However, Syneos Health experts contend that FSP partnerships also offer benefits to smaller companies. Learn how: https://lnkd.in/ge35tk-f #SyneosHealth

Large pharmaceutical companies often favor adopting functional service provider (FSP) models over full-service outsourcing across their clinical and R&D operations. However, Syneos Health experts contend that FSP partnerships also offer benefits to smaller companies. Learn how: https://lnkd.in/ge35tk-f #Syneoshealth

Another successful year representing Medix™ at Asembia's Specialty Pharmacy Summit, #AXS24! I appreciate all the thought leaders and executives that provided valuable insights on how to improve access and patient outcomes in the growing pharmaceutical industry. Let's talk about the importance of Human Capital and how you are going to tackle key workforce initiatives! #HumanCapital #Staffing #PBM #SpecialtyPharmacy #Commercialization

Patient Support Programs (PSPs) are essential in bridging the gap between healthcare professionals, pharmaceutical companies, and patients while navigating their treatment journey. To ensure optimal outcomes, implementing a Best Practice Framework is crucial. Read the full article written by Charlotte Cully in our latest newsletter here: https://lnkd.in/g2FkgqWc Send us a message to book a consultation to develop a framework for your program! Nicole Serena #PSP #PatientSupport #Healthcare #BestPracticeFramework

The UK's NHS is undergoing transformative changes; with shifting policies, resource constraints and growing patient needs. Now, more than ever, the pharmaceutical industry's partnership choices hold the key to maximising the impact of their engagement with the NHS and its impact on patients’ lives. Selecting the right partners is not only about aligning needs to expertise, but also about shared values, patient-centricity and a commitment to advancing medical care. Collaborations rooted in strategic alignment and a deep understanding of the NHS's challenges can yield innovative solutions that truly make a difference. At NeoHealthHub, we have been doing this for over a decade and our holistic suite of offerings enables us to support our clients with strategy through to execution. Speak to us today to understand how we could help you: https://lnkd.in/dHXCHJU #HealthcarePartnerships #NHSUK #InnovationInHealthcare #PharmaceuticalIndustry #CollaborationForChange NeoNavitas | NeoN | NeoSypher | NeoOptima

In the dynamic landscape of pharmaceutical launches, the expertise of Field Reimbursement Managers (FRMs) is crucial. These professionals are at the heart of ensuring patients can swiftly access new treatments. With EVERSANA’s new model, FRMs are empowered to compliantly access our ACTICS eAccess platform and redefine the patient access journey. This innovative platform boasts a 90% success rate in identifying coverage, streamlining the benefits verification process with direct digital connections to over 1,400 payers. It’s a game-changer for FRMs, enhancing their ability to facilitate patient access and expedite therapy initiation. Learn more about ACTICS eAccess: https://lnkd.in/geEsFpxZ As your team gears up for an exciting new pharmaceutical launch or expansion, let’s acknowledge the amplified impact FRMs have when equipped with EVERSANA’s ACTICS eAccess. They adeptly manage the intricacies of payer systems, ensuring patients don’t just reach but also start their therapy journey without unnecessary delays. Drop me a message or comment below to schedule a meet-up at Asembia! #Pharmaceuticals #PatientAccess #FieldReimbursement #Asembia24 #Networking  

SCALE Payer and Regulatory Research tracks major healthcare policy changes that affect coverage and payment for providers, specialists, payers, and pharmaceutical manufacturers. Here is a summary of the most important federal and state policy updates in recent weeks. Check out the November 2023 updates -->https://lnkd.in/eVu_rPD7

Are you planning to reignite a mature brand? As mentioned in a recent post by NeoNavitas' Director of Client Management, Steven Clifford, this can be a challenging time for pharmaceutical companies to know which strategy to adopt. Through our expert teams at NeoSypher, NeoN, and NeoNavitas, we are uniquely positioned to support our clients with quantitative and qualitative insight generation, value proposition consultancy and then execution of the resulting strategy through rapid NHS engagement. Contact us to learn more: https://lnkd.in/dHXCHJU #consultancy #insights #NHS #maturebrands

3 Reasons Why The Biopharma M&A Market Is Ready For Takeoff MedCityNews describes how healthcare M&A activity is expected to increase in the coming months, particularly in the biopharma sector. Read the full article HERE. Key Takeaways: M&A lawyer Matt Gardella predicts robust biopharma M&A due to a looming patent cliff, shrinking valuations, and a weak IPO market. Overall M&A activity in the healthcare sector has been slow this year, with Q2 2023 seeing the lowest number of deals in three years. Large pharmaceutical companies are concerned about a...